Phase 2 Trial Suggests TTFields-Chemotherapy Combo May Improve Outcomes in Recurrent Ovarian Cancer

Phase 2 Trial Suggests TTFields-Chemotherapy Combo May Improve Outcomes in Recurrent Ovarian Cancer
Combining Tumor Treating Fields (TTFields), a method that uses electric fields to disrupt cell division, with Taxol (paclitaxel) may be a promising treatment approach for ovarian cancer patients, according to recent data from a Phase 2 trial. The trial shows that the combo therapy is tolerable and safe for patients with recurrent ovarian cancer, improving patients’

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *